In addition, all sorts of attempts at pharmacological manipulation of the adiponectin pathway designed to raise adiponectin levels in the treatment of obesity-related diseases or reducing insulin resistance in type 2 diabetes may have important negative consequences [54]. This evidence concerns the gene ADIPOQ and Insulin resistance.